 |
| April
7, 2026 |
| Regional
intelligence on Drugs, Diagnostics,
Devices & Digital Health |
|
|
|
* may need subscription to view |
 |
| Boston's
most flexible contract vivarium
lab space: Start with a few study
cages and grow. |
|
Learn More
→ |
|
|
- Affinia Therapeutics: Receives Approval From
Health Canada to Initiate the UPBEAT Trial, a
Phase 1/2 Clinical Trial to Investigate
AFTX-201 as a Treatment for BAG3-Associated
Dilated Cardiomyopathy (DCM) More
- Agenus: Data From Phase II Study of BOT+BAL
in Combination With agent-797 in PD-1
Refractory Gastroesophageal Cancer to be
Presented at AACR 2026
More
- AIRNA: First Patient Dosed in Phase 1 Trial
of AIR-001, Potential Best-in-Class
RNA-Editing Therapy for Alpha-1 Antitrypsin
Deficiency (AATD) More
- Alloy Therapeutics: Enters Into
Multi-Target Collaboration and License
Agreement With Biogen for Use of Alloy’s
AntiClastic ASO Platform More
More
- Alzheon: Advances Industry-Leading Portfolio
of Oral Anti-Amyloid Aggregation Inhibitors With
First Subject Dosed in Phase 1 of ALZ-507,
Highlighting Potential for Once-Daily
Administration, Improved Safety and Efficacy,
and APOE4 Corrector Mechanism More
- Avalyn: Appoints Jon Congleton, Seasoned
Biopharmaceutical Executive, to Its Board of
Directors More
- Bio-IT World: 25th Annual Bio-IT World
Conference & Expo in Boston Leads the
Conversation on Operationalizing AI Across
Real-World Drug Discovery Environments More
- Bruker: Invests in Photothermal AFM-IR to
Advance Semiconductor Research More
- Climb Bio: FDA Fast Track Designation for
Budoprutug for the Treatment of Primary
Membranous Nephropathy More
- Corbus Pharmaceuticals: Broad Alignment With
FDA on Registration Path for CRB-701 in
Second-Line HNSCC and Cervical Cancer More
- Dana-Farber: Preclinical Research Finds
Opportunities for Treatment Improvements for
HER2-positive Breast Cancer More
- enGene: Name Change to enGene Therapeutics
Inc. More
- Fortitude Biomedicines: Lead Program
Targeting Disease-Driven T-cell Signaling
Pathways for the Treatment of Axial
Spondyloarthritis More
- Hologic: Chief Executive Officer Steve
MacMillan to Retire Upon Close of Go-Private
Transaction More
More
- Inogen: Appointment of Vafa Jamali to Board
of Directors More
- Minerva: Leadership Transition More
- NeuroSense: Granted Brazilian Patent
Covering PrimeC Composition More
- Nuvalent: Submission of New Drug Application
to FDA for Neladalkib in TKI Pre-treated
Advanced ALK-positive NSCLC More
- Organogenesis: Achieves Primary Endpoint in
Randomized Controlled Trial of PuraPlyAM More
- Organogenesis: Successful FDA Meeting and
Plan to File BLA for ReNu for Knee
Osteoarthritis Pain More
- Perceptive Discovery: Expands In Vitro
Capabilities at Needham, MA Site to Accelerate
Preclinical Oncology Research More
- Praxis Precision Medicines: Positive Results
From the EMBRAVE Part A Trial of Elsunersen in
Patients With SCN2A Early-Onset Developmental
and Epileptic Encephalopathy More
More* More*
- Regeneron: Collaborates With TriNetX to
Access De-Identified Electronic Health Records
of 300 Million Patients to Drive Research and
Product Development in Life Sciences and
Digital Health Solutions More
- Rhythm Pharmaceuticals: Changes to Board of
Directors More
- Thermo Fisher Scientific: Introduces the
Gibco CTS Compleo Fill and Finish System to
Help Streamline Cell Therapy Manufacturing More
- Vedanta Biosciences: Phase 3 RESTORATiVE303
Study of VE303 for the Prevention of Recurrent
C. difficile Infection Will Continue as
Planned Following Protocol-Specified Interim
Analysis More
|
|
 |
We
help you focus on the science.
Let Charles River CFO
provide the financial insight you
need.
Flexible fractional and
interim solutions. |
|
Learn More
→ |
|
|
- Akebia Therapeutics: Inducement Grants Under
Nasdaq Listing Rule 5635(c)(4) More
- Anika: Inducement Grants Under Nasdaq
Listing Rule 5635(c)(4) More
- Apnimed: Secures Up to $150 Million in Debt
Financing With HealthCare Royalty Partners to
Support Planned AD109 Commercial Launch More
- Auxilium Expands Downtown Worcester
Footprint After Pivot Toward Life Sciences More*
- Beacon Biosignals: Upsizes Series B
Financing to Over $97 Million
More
- Bicara Therapeutics: Inducement Grant Under
Nasdaq Listing Rule 5635(c)(4) More
- Biotech Layoff Pick Back Up As 14 Companies
Cut 745 Jobs in Q1 More*
- Candel Therapeutics: Inducement Grants Under
Nasdaq Listing Rule 5635(c)(4) More
- Four Flagship Biotechs Leaving Boston,
Cambridge for New Watertown Digs More*
- Intellia Therapeutics: Inducement Grants
Under Nasdaq Listing Rule 5635(c)(4)
More
- KalVista Pharmaceuticals: Inducement Grants
Under Nasdaq Listing Rule 5635(c)(4) More
- Mass. Companies Close Major Deals in
Biotech, Media in March More*
- Praxis Precision Medicines: Inducement
Grants Under Nasdaq Listing Rule 5635(c)(4) More
- Spyre Therapeutics: Grants of Inducement
Awards More
- Stipple Bio: Emerges From Stealth With
Oversubscribed $100 Million Series A
Financing to Advance STP-100 Into Early
Clinical Studies and Advance a Precision
Oncology Pipeline That Leverages its
Pointillist Platform More
More More*
More*
- SV Health Investors: Acquires EpiVax More
- Takeda Tears Up Denali Partnership,
Returning Dementia Asset Amid Restructuring
More
More*
- Verastem Oncology: Inducement Grants Under
Nasdaq Listing Rule 5635(c)(4) More
- Vericel: BARDA Award Valued at up to $197
Million for Procurement and Advanced
Development of NexoBrid More
- Xilio Therapeutics: Inducement Grants Under
Nasdaq Listing Rule 5635(c)(4) More
|
|
|
 |
Pace®
Life Sciences
The CDMO That Takes You Further.
Your partner for Product
Development, Manufacturing,
Analytical Testing, Regulatory
Consulting & Operational
Support. |
|
Learn More
→ |
|
|
- BioPharmGuy News: Moon Rocket, Fake Masters,
Organ Sacks, Fly Brain, Dead Tortoise More
- Biotech Hangout: Episode 178 Podcast
- Flagship Pioneering Snags Another
Massachusetts Life Sciences Leader More*
- Machine Learning and Single-Cell Technology
Combined to Drive High-Performance Cell Line
Development
More
- Subscribe to LifeSci Startup for
Updates on US Startups More
|
|
 |
| Life
Sciences Talent and Consulting
Strategist George Quinn Named
Partner, Fractional Talent at
Slone Partners |
|
Learn More
→ |
|
|
- AI in Biotech: The New Frontier for
Leadership & Strategy More
- Empowering Students Through STEM: A
Conversation With Massachusetts Science &
Engineering Fair Executive Director Helen
Rosenfeld More
- From Seed to Series C: What
Investors Look for Beyond the Science More
- ICYMI: CEO’s Perspective: Big Moves Come
with Big Responsibility More
- ICYMI: CEO’s Perspective: The High Cost of
Job Hopping More
- ICYMI: Elevating Executive Presence: A
Blueprint for Life Sciences and Biotech
Leaders More
- Lilly’s Chief Technology Officer Retires
After 35 Years; Astellas Strategy Exec Resigns
More*
- M&A in Life Sciences: The Turning Tide –
Why Now is a Strategic Inflection for
Biopharma and Biotech More
- More Than Executive Search: Building
Leadership for Every Stage of Growth More
- The Rise of Fractional Talent in Life
Sciences: What to Expect in 2026 More
|
|
|
DISCOVER COMPANIES |
|
Big4Bio: Boston Life Science
Company Directory |
|
Locate a specific company or
explore new companies in life
science. |
|
Explore
our Company Directory
|
Provided courtesy
of
 |
|
|
|
 |
|
|
|
You are
receiving this email because
you signed up for one of our
newsletters at Big4Bio.com,
signed up at one of our
partner or sponsor events,
or given as a gift
subscription by your firm or
organization. Unsubscribe
Big4Bio:Boston,
all rights reserved 2026
© 2026
Big4Bio, a division of
BigBio Communications. All
rights reserved.
|
|
|
|
|
